Feedback / Questions
SENTI-301A - Senti Bio
https://www.globenewswire.com/news-release/2024/12/16/2997466/0/en/Senti-Bio-Announces-First-Patient-Dosed-in-Clinical-Trial-of-SN301A-in-Hepatocellular-Carcinoma-in-Collaboration-with-Celest-Therapeutics.html
Dec 16, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next